By 2020, demonstrate that the transmission of leprosy and malaria can be interrupted, and the new interventions pioneered by the Novartis Foundation and partners can be integrated into national programs.
By end 2016, establish a plan and partnership for the development of a leprosy diagnostic test.
Intensify the fight against leprosy by demonstrating the feasibility of an innovative approach toward zero transmission of leprosy in several sites across Asia, Africa and Latin America; and by continuing to provide free multidrug therapy (MDT) to all leprosy patients through WHO by 2020.
By 2017, launch a digital health strategy, including key publications providing sector guidance on policy and programmatic implementation when incorporating information communication technology (ICT)/digital health in low and middle-income countries (LMICs).
Pioneer “Targeted Parasite Elimination” in Namibia to build the knowledge to shrink the malaria map by 2018.
In partnership with local experts, screen 3,000 children for Rheumatic Heart Disease (RHD) in 50 schools in Zambia by 2016. Enroll up to 20 local clinics in RHD prevention study. Hold second expert workshop with Pan-African Society of Cardiology, WHO and African Union to implement RHD prevention and treatments strategies according to RHD policy roadmap developed in 2015.1
In 2016, invest USD 5 million in scientific and clinical capacity building in the developing world (e.g. clinical study sites, epidemiology, and drug discovery-related scientific areas).
In 2016, foster best practice sharing among National Malaria Control Program managers from at least 25 countries to improve malaria controls and elimination programs.
By 2017, complete one pilot of SMS For Life 2.0 involving at least 300 healthcare facilities and initiate additional pilots in at least two countries in sub-Saharan Africa. Pilots are to deliver training on medicine stock management as well as disease surveillance to healthcare workers via tablet computers.
Donate products to more than 1,500 medical missions from 2014 to 2016, enabling more than 80,000 cataract surgeries to be performed among underserved populations.
Supply 20 million tablets of dispersible amoxicillin (Amoxicillin 250 mg DT) to UNICEF to reach up to 1 million children by March 2016, ultimately supporting the reduction of deaths among children under 5 from infectious diseases, including pneumonia.2
Donate medicines to more than 15,000 patients that cannot afford their medication through Alcon’s Patient Assistance Program in the US each year between 2014-2016.
Launch 100 discounted pricing access schemes (Patient Assistance Programs and Managed Entry Agreements) for medicines in emerging markets during 2014-2016.
Launch Novartis Access in 30 countries and reach 20 million patients by the end of 2020. In 2016, introduce Novartis Access in five additional countries and file 400 submissions to prepare launch in 20 countries.
In 2016, expand the Novartis Access portfolio to include products from all Novartis Divisions; assess extension into new areas based on external partner feedback; include at least one additional on-patent pharmaceutical treatment in the portfolio.
In 2016, reach agreement on methodology for measurement and evaluation of Novartis Access and conduct a baseline study in Kenya together with Boston University. Put in place mechanisms to ensure final price paid by patients in Kenya stays below USD 1.50 per treatment per month.
In 2016, test and validate a replicable surveillance system for supply chain integrity in Kenya together with Management Sciences for Health. In addition, raise awareness on non-communicable diseases (NCDs) and build capacity in Kenya in collaboration with the Red Cross and Kenya Conference of Catholic Bishops (KCCB). Explore additional partnerships on innovative financing models and distribution chain integrity.
Provide health education to 12 million people through at least 300,000 community education meetings in rural communities across Kenya, India, Indonesia and Vietnam by 2016.3
By 2025, develop and validate at least one innovative healthcare delivery model that addresses the double burden of disease in underserved populations and contributes to the WHO goal of 25% reduction in non-communicable diseases (NCDs) mortality by 2025.
Develop roadmap in Ghana for nationwide scaling of telemedicine project, in expansion phase to reach national scale by 2017 by inclusion in Ghana Health Services.
By 2017, address large burden of hypertension in Ghana to test a community-based model using information communication technology (ICT) to enhance capacity of private sector, Ghana Health Service (GHS) and individuals.
Provide medications worth USD 1.5 billion to about 170,000 patients through the Novartis Patient Assistance Foundation, Inc. between 2014-2016.
Explore outcomes-based business models for major diseases in at least 10 out of our top 25 markets (3 in 2016, 3 in 2017, 4 in 2018).
Provide medications to more than 85,000 patients in low- and middle-income countries through the Novartis Oncology Access program in 2016.
In 2016, continue conducting Basic Emergency Obstetric and Newborn care training of 100 midwives in Ethiopia to serve pregnant women since the activities started in 2015. In addition, upgrade 10 health centers and create awareness in the community of the health center upgrading programs, while ensuring ongoing availability of medicines.
Initiate filing submission of approximately 50 local, affordable brands of existing medicines during 2014-2016, and launch approximately 45 affordable original brands of existing medicines in 2015-2017.4
In 2016, invest USD 20-25 million to discover and develop medicines for neglected diseases and make the drugs available at affordable prices in countries where the diseases are endemic when and if they are approved for use.
Until 2019, continue to develop key clinical compounds, such as clofazimine to treat drug resistant tuberculosis and make successful compounds available at affordable costs in developing world countries where the diseases are endemic.
Assess safety and efficacy of anti-malarial development compounds KAE609 and KAF156 as treatment and prevention of malaria, considering existing and new combination partners.
Sign collaborative agreements with governments at a Federal / Regional level or with key institutions in key countries in Latin America to drive investment for the respective country and elevate health-related efforts for its citizens in order to position Novartis as trusted/strategic partner. The focus for 2016-2017 is to manage the progress and results of current agreements signed in the region (e.g. Mexico) and explore developing similar initiatives in other countries.
Build alliance called “Pacientes Todos” (We’re all Patients) with other pharmaceutical companies to develop a holistic approach for capacity building for patient advocacy groups (PAGs) in Latin America (through an online platform and local/ regional workshops) in 4 countries by 2017. Capability building includes workshops on sustainability of the organizations & funding, communication strategy, advocacy and ultimately implementing learnings through a key advocacy initiative.
In 2016, further strengthen discussions with stakeholders to shape healthcare system reforms focusing on improving patient outcomes.
In 2016, engage in regulatory and policy discussions on key science & innovation regulations to foster a framework conducive to patient access:
- Pioneer regulatory framework for cell & gene therapies
- Support EU and US legislative attempts to modernize regulatory framework (“21st century regulation”)
- Foster IP policy conducive to innovative research
During 2014-2016, drive advocacy activities linked to World Sight Day in at least 20 countries, to highlight the importance of eye health through community-based events, broader corporate messaging and support, and by partnering with key NGOs.